WO2011045232A3 - Agonistes du récepteur du neuropeptide-2 (y-2r) - Google Patents

Agonistes du récepteur du neuropeptide-2 (y-2r) Download PDF

Info

Publication number
WO2011045232A3
WO2011045232A3 PCT/EP2010/065060 EP2010065060W WO2011045232A3 WO 2011045232 A3 WO2011045232 A3 WO 2011045232A3 EP 2010065060 W EP2010065060 W EP 2010065060W WO 2011045232 A3 WO2011045232 A3 WO 2011045232A3
Authority
WO
WIPO (PCT)
Prior art keywords
neuropeptide
agonists
receptor
obesity
diabetes
Prior art date
Application number
PCT/EP2010/065060
Other languages
English (en)
Other versions
WO2011045232A2 (fr
Inventor
Karin Conde-Knape
Waleed Danho
Nader Fotouhi
David C. Fry
Wajiha Khan
Anish Konkar
Cristina Martha Rondinone
Joseph Swistok
Jefferson Wright Tilley
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to EP10770751A priority Critical patent/EP2488195A2/fr
Priority to JP2012533580A priority patent/JP2013507414A/ja
Priority to CN2010800462458A priority patent/CN102596228A/zh
Priority to CA2776302A priority patent/CA2776302A1/fr
Priority to IN3042DEN2012 priority patent/IN2012DN03042A/en
Publication of WO2011045232A2 publication Critical patent/WO2011045232A2/fr
Publication of WO2011045232A3 publication Critical patent/WO2011045232A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des agonistes du récepteur du neuropeptide-2 représentés par la formule (I) : ainsi que des sels de qualité pharmaceutique, des dérivés et des fragments de ceux-ci, dans laquelle formule les substituants sont tels qu'indiqués dans la description. Ces composés, et les compositions pharmaceutiques les contenant, sont utiles pour le traitement de maladies telles que par exemple l'obésité et le diabète.
PCT/EP2010/065060 2009-10-13 2010-10-08 Agonistes du récepteur du neuropeptide-2 (y-2r) WO2011045232A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP10770751A EP2488195A2 (fr) 2009-10-13 2010-10-08 Agonistes du récepteur du neuropeptide-2 (y-2r)
JP2012533580A JP2013507414A (ja) 2009-10-13 2010-10-08 神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト
CN2010800462458A CN102596228A (zh) 2009-10-13 2010-10-08 神经肽-2受体(y-2r)激动剂
CA2776302A CA2776302A1 (fr) 2009-10-13 2010-10-08 Agonistes du recepteur du neuropeptide-2 (y-2r)
IN3042DEN2012 IN2012DN03042A (fr) 2009-10-13 2010-10-08

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25089609P 2009-10-13 2009-10-13
US61/250,896 2009-10-13

Publications (2)

Publication Number Publication Date
WO2011045232A2 WO2011045232A2 (fr) 2011-04-21
WO2011045232A3 true WO2011045232A3 (fr) 2011-06-16

Family

ID=43478048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/065060 WO2011045232A2 (fr) 2009-10-13 2010-10-08 Agonistes du récepteur du neuropeptide-2 (y-2r)

Country Status (7)

Country Link
US (1) US20110172147A1 (fr)
EP (1) EP2488195A2 (fr)
JP (1) JP2013507414A (fr)
CN (1) CN102596228A (fr)
CA (1) CA2776302A1 (fr)
IN (1) IN2012DN03042A (fr)
WO (1) WO2011045232A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5902194B2 (ja) 2010-12-16 2016-04-13 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
ES2952874T3 (es) 2012-03-22 2023-11-06 Novo Nordisk As Composiciones de péptidos GLP-1 y preparación de estas
EP2708243A1 (fr) * 2012-09-17 2014-03-19 OntoChem GmbH Molécules cytotoxiques liés à un ligand de récepteur
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
MX369818B (es) 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
JP6629198B2 (ja) 2013-11-15 2020-01-15 ノヴォ ノルディスク アー／エス ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AR104984A1 (es) 2015-06-12 2017-08-30 Novo Nordisk As Compuestos selectivos para pyy y sus usos
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
CN109678930B (zh) * 2018-12-05 2022-04-29 西北工业大学 聚乙二醇修饰的npff及其用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026778A1 (fr) * 1993-05-10 1994-11-24 Protein Delivery, Inc. Compositions polypeptidiques stabilisees par couplage
EP1319667A2 (fr) * 2001-12-07 2003-06-18 Development Center For Biotechnology Procédé pour la synthèse en phase solide de conjugués peptide-espaceur-lipide, les conjugués synthésisée par ledit procédé, et liposomes cibles contenant ledit conjugués
WO2006049681A2 (fr) * 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Agonistes recepteur y2 neuropeptidiques selectifs
WO2006077035A1 (fr) * 2005-01-18 2006-07-27 F.Hoffmann-La Roche Ag Peptides a activite agoniste du recepteur du neuropeptide (y2r)
WO2006091505A2 (fr) * 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Agonistes du recepteur y de neuropeptide
WO2007065808A2 (fr) * 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Agonistes du récepteur du neuropeptide-2
WO2009035347A1 (fr) * 2007-09-11 2009-03-19 Cristina-Simona Weinberg Constructions peptidiques-lipidiques et leur utilisation pour des applications diagnostiques et thérapeutiques
WO2010052144A2 (fr) * 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB779829A (en) 1953-11-20 1957-07-24 Ciba Ltd Polyglycol ethers and their manufacture
BE667886A (fr) 1965-04-23
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5962263A (en) * 1998-01-08 1999-10-05 Incyte Pharmaceuticals, Inc. Human membrane recycling proteins
EP2626368B1 (fr) 2004-07-19 2016-12-21 Biocon Limited Conjugués insuline-oligomère, formulations et utilisations de ceux-ci

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026778A1 (fr) * 1993-05-10 1994-11-24 Protein Delivery, Inc. Compositions polypeptidiques stabilisees par couplage
EP1319667A2 (fr) * 2001-12-07 2003-06-18 Development Center For Biotechnology Procédé pour la synthèse en phase solide de conjugués peptide-espaceur-lipide, les conjugués synthésisée par ledit procédé, et liposomes cibles contenant ledit conjugués
WO2006049681A2 (fr) * 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Agonistes recepteur y2 neuropeptidiques selectifs
WO2006077035A1 (fr) * 2005-01-18 2006-07-27 F.Hoffmann-La Roche Ag Peptides a activite agoniste du recepteur du neuropeptide (y2r)
WO2006091505A2 (fr) * 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Agonistes du recepteur y de neuropeptide
WO2007065808A2 (fr) * 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Agonistes du récepteur du neuropeptide-2
WO2009035347A1 (fr) * 2007-09-11 2009-03-19 Cristina-Simona Weinberg Constructions peptidiques-lipidiques et leur utilisation pour des applications diagnostiques et thérapeutiques
WO2010052144A2 (fr) * 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations

Also Published As

Publication number Publication date
CN102596228A (zh) 2012-07-18
EP2488195A2 (fr) 2012-08-22
JP2013507414A (ja) 2013-03-04
US20110172147A1 (en) 2011-07-14
WO2011045232A2 (fr) 2011-04-21
IN2012DN03042A (fr) 2015-07-31
CA2776302A1 (fr) 2011-04-21

Similar Documents

Publication Publication Date Title
WO2007065808A3 (fr) Agonistes du récepteur du neuropeptide-2
WO2011045232A3 (fr) Agonistes du récepteur du neuropeptide-2 (y-2r)
WO2010052144A3 (fr) Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations
WO2009010416A3 (fr) Inhibiteurs de 11b-hydroxystéroïde déshydrogenase
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
MY149622A (en) Pyrazoles as 11-beta-hsd-1
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
WO2007060140A3 (fr) Inhibiteurs de diacylglycérol acyltransférase (dgat)
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
HK1158192A1 (en) Piperidine gpcr agonists
WO2008135791A8 (fr) Imidazoquinolines dotées de propriétés immuno-modulatrices
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2007082808A3 (fr) Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
MX2011012122A (es) Derivados de tiofeno.
WO2007003962A3 (fr) Agonistes de gpcr
WO2007003961A3 (fr) Agonistes de gpcr
GB0812642D0 (en) Compounds
WO2007141283A3 (fr) Nouveaux sels et formes de sels cristallins d'un dérivé de l'indolinone
WO2007150026A3 (fr) Dérivés de purinone en tant qu'agonistes de hm74a
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
IN2012DN03182A (fr)
IN2012DN02139A (fr)
HK1146049A1 (en) Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080046245.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10770751

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010770751

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2776302

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 3042/DELNP/2012

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012533580

Country of ref document: JP